NEW YORK – As the diagnostics space trends more toward liquid biopsy, companies are shifting focus from using the technology to detect advanced stage disease to trying to discover earlier stage disease.
Foundation Medicine, a Roche subsidiary, took a step in that direction with its acquisition of Lexent Bio earlier this month, a decision that stemmed from "a desire to have more of a multiomic approach to our diagnostic portfolio," said Foundation's Chief Scientific Officer Priti Hegde.